Block Clinical
Block Clinical is recorded as a service provider in 14 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 14 of 14 trials · Latest update first
A Phase 2 Open-Label, Multicenter Clinical Study of The Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress
Sponsor Seaport Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress
Sponsor Seaport Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
Sponsor CSL Behring LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
(Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
Sponsor Cogent Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies.
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia
Sponsor Larimar Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
Sponsor CSL Behring LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa
Sponsor Beacon Therapeutics (USA) Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Block Clinical?
The 2026-10-09 snapshot links Block Clinical to 14 distinct CTIS trials. Recorded services include Patient travel reimbursement, transport service, Payment services, Patient Concierge Service. Travel and Reimbursement Services, Patient concierge services, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Block Clinical?
The most frequently recorded therapeutic areas are Psychiatry, Blood Disorders, Genetic and Congenital Disorders, Haematological Malignancies. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Block Clinical conducted?
The linked trials record locations in 18 countries, including Germany, Poland, Spain, France, Belgium. These are trial locations, not confirmed office locations or countries where Block Clinical delivered services.
What can this page tell me about Block Clinical's trial experience?
Browse 14 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Block Clinical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Block Clinical Inc.